CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10110|
|Indication||Locally Advanced or Metastatic Breast Cancer|
|Funding Request||For hormonal treatment of non-visceral locally advanced or metastatic HER2- breast cancer in postmenopausal women, regardless of age, who have not been previously treated with endocrine therapy|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|NOC Date||November 8, 2017|
|Manufacturer||AstraZeneca Canada Inc.|
|Sponsor||AstraZeneca Canada Inc.|
|Submission Date||July 17, 2017|
|Submission Deemed Complete||July 24, 2017|
|Submission Type||New Drug|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||July 31, 2017|
|Check-point meeting||September 18, 2017|
|pERC Meeting||November 16, 2017|
|Initial Recommendation Issued||November 30, 2017|
|Feedback Deadline ‡||December 14, 2017|
|pERC Reconsideration Meeting||January 18, 2018|
|Final Recommendation Issued||February 1, 2018|
|Notification to Implement Issued||February 16, 2018|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.